Advertisement

Mesothelioma pp 235-242 | Cite as

Targeting Angiogenesis in Malignant Pleural Mesothelioma

  • Arnaud ScherpereelEmail author
Chapter

Abstract

Malignant pleural mesothelioma (MPM) is a quite rare cancer but with increasing incidence worldwide, usually associated with previous asbestos exposure. MPM patients have globally a poor prognosis with limited therapeutic options and no validated curative treatment. Therefore, innovative drugs and strategies are needed. Based on the preclinical rationale and first-trial data, antiangiogenic drugs have been tested in MPM, mostly associated with standard frontline chemotherapy (cisplatin/pemetrexed). However, if anti-VEGF antibody (bevacizumab) exhibited a real value in addition with first-line chemotherapy in a large phase III trial, other drugs’ and trials’ results did not support the use of this class of targeted therapies so far. Moreover, there are no biomarkers to date to predict the efficacy of antiangiogenic drugs in MPM patients. Future directions include the evaluation of antiangiogenic drugs in combination with immunotherapy in MPM.

Keywords

Malignant pleural mesothelioma Treatment Angiogenesis 

References

  1. 1.
    Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–6.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397–408.CrossRefGoogle Scholar
  3. 3.
    Andujar P, Lacourt A, Brochard P, Pairon J-C, Jaurand M-C, Jean D. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. J Toxicol Environ Health B Crit Rev. 2016;19(5–6):151–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–95.CrossRefGoogle Scholar
  5. 5.
    Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v31–9.CrossRefGoogle Scholar
  6. 6.
    van Zandwijk N, Clarke C, Henderson D, Musk W, Fong K, Nowak AK, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254–307.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73:i1–i30.PubMedCrossRefGoogle Scholar
  8. 8.
    Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1343–73.CrossRefGoogle Scholar
  9. 9.
    NCCN Malignant pleural mesothelioma guidelines. Version 2.2018 — February 26, 2018. https://www.nccn.org/professionals/physician_gls/pdf/mpm_blocks.pdf. Accessed 09 Sept 2018.
  10. 10.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44.CrossRefGoogle Scholar
  11. 11.
    Scherpereel A, Mazieres J, Greillier L, Gervais R, Bylicki O, Monnet I, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol. 2017;35(18_suppl):LBA8507.CrossRefGoogle Scholar
  12. 12.
    Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collov E, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012;75(3):360–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6.CrossRefGoogle Scholar
  15. 15.
    Levin PA, Dowell JE. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. Onco Targets Ther. 2017;10:2057–66.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Hendry SA, Farnsworth RH, Solomon B, et al. The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. 2016;7:621.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Li C, Liu T, Bazhin AV, Yang Y. The sabotaging role of myeloid cells in anti-angiogenic therapy: coordination of angiogenesis and immune suppression by hypoxia. J Cell Physiol. 2017;232(9):2312–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 1999;189(1):72–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer. 2001;85(6):863–8.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999;81(1):54–61.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Soini Y, Puhakka A, Kahlos K, et al. Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1. Histopathology. 2001;39(2):179–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012;32(12):1095–111.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161–e72.PubMedCrossRefGoogle Scholar
  24. 24.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14.CrossRefGoogle Scholar
  25. 25.
    Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013;14(6):543–51.PubMedCrossRefGoogle Scholar
  26. 26.
    Buikhuisen WA, Scharpfenecker M, Griffioen AW, Korse CM, van Tinteren H, Baas P. A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes. J Thorac Oncol. 2016;11(5):758–68.PubMedCrossRefGoogle Scholar
  27. 27.
    Tsao AS, Moon J, Wistuba I, Vogelzang NJ, Kalemkerian G, Redman M, et al. Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2017;12(8):1299–308.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Tsao AS, Miao J, Wistuba I, Vogelzang NJ, Heymach J, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel SM, Weber Redman M, Gandara DR, Kelly K. SWOG S0905: a randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. Abstract ASCO 2018. J Clin Oncol. 2018;36(suppl):abstr 8514.CrossRefGoogle Scholar
  29. 29.
    Grosso F, Steele N, Novello S, Kowak AK, Popat S, Greillier L, et al. Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-meso trial. J Clin Oncol. 2017;35:3591–600.PubMedCrossRefGoogle Scholar
  30. 30.
    Papa S, Popat S, Shah R, Prevost AT, Lal R, McLennan B, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol. 2013;8(6):783–7.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, et al. A phase II study of sorafenib in malignant mesothelioma: results of cancer and leukemia group B 30307. J Thorac Oncol. 2010;5(10):1655–61.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, et al. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014;15(3):197–201.CrossRefGoogle Scholar
  33. 33.
    Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113(4):808–14.CrossRefGoogle Scholar
  34. 34.
    Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475–88.CrossRefGoogle Scholar
  35. 35.
    Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30(20):2509–15.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004–11.PubMedCrossRefGoogle Scholar
  37. 37.
    Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14(3):263–73.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013;109(3):552–8.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Dowell JE, Dunphy FR, Taub RN, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012;77(3):567–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Westeel V, Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Morin F, Zalcman G, French Cooperative Thoracic Intergroup (IFCT). Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial. J Clin Oncol. 2018;36(suppl):abstr 8505.CrossRefGoogle Scholar
  41. 41.
    Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? Eur Respir Rev. 2018;27(147):170098.PubMedCrossRefGoogle Scholar
  42. 42.
    Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer. 2005;48:291–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385):eaak9679.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M, IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pulmonary and Thoracic Oncology DepartmentUniv Lille, CHU LilleLilleFrance
  2. 2.French National Network of Clinical Expert Centers for Malignant Pleural Mesothelioma Management (MESOCLIN)LilleFrance

Personalised recommendations